Loading clinical trials...
Loading clinical trials...
A Phase 4 Safety Study Assessing the Adverse Events Occurring Within One Day of TEGSEDI Administration in Patients With Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)
Conditions
Interventions
TEGSEDI
Locations
2
United States
Study Center
Rosedale, New York, United States
Study Center
Toronto, Ontario, Canada
Start Date
January 21, 2021
Primary Completion Date
March 20, 2024
Completion Date
March 20, 2024
Last Updated
April 10, 2025
Lead Sponsor
Akcea Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions